Related Experiment Videos
Cost savings with nefazodone in treating depression
Robert E Hales1, Donald M Hilty, Gregory H Brunson
1Department of Psychiatry, University of California, Davis, Sacramento 95817, USA. rehales@ucdavis.edu
The Journal of Clinical Psychiatry
|March 14, 2002
Summary
Nefazodone offers a cost-effective approach to depression treatment by reducing costs associated with treatment failure and side effects. This antidepressant also improves sleep and reduces anxiety, lowering the need for other medications.
Area of Science:
- Pharmacoeconomics
- Psychiatry
- Clinical Pharmacy
Background:
- Antidepressant therapy selection requires considering drug costs, treatment failure, and side effect management.
- The growing number of antidepressants necessitates comprehensive economic evaluations.
Purpose of the Study:
- To evaluate the pharmacoeconomic impact of nefazodone compared to other antidepressants.
- To assess the cost-effectiveness of nefazodone in treating depression, including associated symptoms and side effects.
Main Methods:
- Economic studies utilizing decision analysis and direct annual cost models.
- Comparison of nefazodone with imipramine and fluoxetine in North American and English cohorts.
Main Results:
- Nefazodone demonstrated a significant impact on depression-related costs compared to imipramine and fluoxetine.
- Early reduction in anxiety and agitation symptoms was observed with nefazodone.
- Improved sleep measures with nefazodone led to less frequent and costly use of anxiolytics or sedative-hypnotics.
Conclusions:
- Nefazodone presents a cost-effective treatment option for depression.
- Nefazodone's efficacy in managing anxiety, agitation, and sleep disturbances contributes to its favorable economic profile.
- Pharmacoeconomic analysis supports nefazodone as a valuable choice in antidepressant therapy.